مصطلحات الفهرس: rituximab/dt [Drug Therapy], vincristine/dt [Drug Therapy], vincristine sulfate/cb [Drug Combination], vincristine sulfate/cm [Drug Comparison], vincristine sulfate/dt [Drug Therapy], bcl2 gene, BCL6 gene, gene rearrangement, Herpes simplex virus, human, lymphoma, maintenance therapy, mantle cell lymphoma/dt [Drug Therapy], multiple myeloma/th [Therapy], myeloma/th [Therapy], New Zealand, oncogene myc, pandemic, patient attitude, priority journal, salvage therapy, screening test, telehealth, vaccination, virus shedding, virus transmission, cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cytarabine/cb [Drug Combination], cytarabine/dt [Drug Therapy], doxorubicin/cb [Drug Combination], doxorubicin/cm [Drug Comparison], doxorubicin/dt [Drug Therapy], etoposide/cb [Drug Combination], etoposide/dt [Drug Therapy], growth factor, ibrutinib/dt [Drug Therapy], ifosfamide/cb [Drug Combination], ifosfamide/dt [Drug Therapy], immunoglobulin, methotrexate/cb [Drug Combination], methotrexate/dt [Drug Therapy], Myc protein/ec [Endogenous Compound], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], protein bcl 2/ec [Endogenous Compound], protein bcl 6/ec [Endogenous Compound], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], venetoclax/dt [Drug Therapy], vincristine/cb [Drug Combination], vincristine/cm [Drug Comparison], AL amyloidosis, antifungal therapy, article, Australian, autologous stem cell transplantation, B cell lymphoma/dt [Drug Therapy], Burkitt lymphoma/dt [Drug Therapy], cancer grading, cancer immunotherapy, cancer radiotherapy, cancer recurrence, chronic lymphatic leukemia/dt [Drug Therapy], coronavirus disease 2019, diagnostic test, diffuse large B cell lymphoma/rt [Radiotherapy], follicular lymphoma/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29271Test
Internal Medicine Journal
Click here for full text options
LibKey Link

مصطلحات الفهرس: rituximab/dt [Drug Therapy], vincristine/dt [Drug Therapy], vincristine sulfate/cb [Drug Combination], vincristine sulfate/cm [Drug Comparison], vincristine sulfate/dt [Drug Therapy], bcl2 gene, BCL6 gene, gene rearrangement, Herpes simplex virus, human, lymphoma, maintenance therapy, mantle cell lymphoma/dt [Drug Therapy], multiple myeloma/th [Therapy], myeloma/th [Therapy], New Zealand, oncogene myc, pandemic, patient attitude, priority journal, salvage therapy, screening test, telehealth, vaccination, virus shedding, virus transmission, cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cytarabine/cb [Drug Combination], cytarabine/dt [Drug Therapy], doxorubicin/cb [Drug Combination], doxorubicin/cm [Drug Comparison], doxorubicin/dt [Drug Therapy], etoposide/cb [Drug Combination], etoposide/dt [Drug Therapy], growth factor, ibrutinib/dt [Drug Therapy], ifosfamide/cb [Drug Combination], ifosfamide/dt [Drug Therapy], immunoglobulin, methotrexate/cb [Drug Combination], methotrexate/dt [Drug Therapy], Myc protein/ec [Endogenous Compound], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], protein bcl 2/ec [Endogenous Compound], protein bcl 6/ec [Endogenous Compound], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], venetoclax/dt [Drug Therapy], vincristine/cb [Drug Combination], vincristine/cm [Drug Comparison], AL amyloidosis, antifungal therapy, article, Australian, autologous stem cell transplantation, B cell lymphoma/dt [Drug Therapy], Burkitt lymphoma/dt [Drug Therapy], cancer grading, cancer immunotherapy, cancer radiotherapy, cancer recurrence, chronic lymphatic leukemia/dt [Drug Therapy], coronavirus disease 2019, diagnostic test, diffuse large B cell lymphoma/rt [Radiotherapy], follicular lymphoma/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29271Test
Internal Medicine Journal
LibKey Link

مصطلحات الفهرس: prednisolone/cb [Drug Combination], adult, aged, article, bone marrow biopsy, cancer combination chemotherapy, cancer immunotherapy, cancer mortality, cancer radiotherapy, cancer recurrence, cancer staging, cohort analysis, comparative effectiveness, controlled study, distant metastasis/co [Complication], female, follicular lymphoma/dt [Drug Therapy], follicular lymphoma/rt [Radiotherapy], follow up, human, human tissue, lymph node metastasis/co [Complication], maintenance therapy, major clinical study, male, monotherapy, multimodality cancer therapy, overall survival, positron emission tomography-computed tomography, priority journal, progression free survival, radiation dose, retrospective study, survival rate, survival time, systemic therapy, treatment failure, treatment outcome, watchful waiting, bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], hemoglobin/ec [Endogenous Compound], prednisolone/dt [Drug Therapy], rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], rituximab/tm [Unexpected Outcome of Drug Treatment], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35979Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: cancer survival, clinical outcome, comorbidity, drug efficacy, drug tolerability, follicular lymphoma/di [Diagnosis], follicular lymphoma/dt [Drug Therapy], human, immunoregulation, infection/si [Side Effect], maintenance therapy, medical decision making, nonhodgkin lymphoma/di [Diagnosis], nonhodgkin lymphoma/dt [Drug Therapy], obinutuzumab/cb [Drug Combination], patient monitoring, patient preference, priority journal, progression free survival, review, second cancer/si [Side Effect], survival time, symptom, T cell depletion, treatment duration, treatment response, tumor volume, bendamustine/ae [Adverse Drug Reaction], bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], CD20 antibody/cb [Drug Combination], CD20 antibody/dt [Drug Therapy], obinutuzumab/dt [Drug Therapy], prednisolone/ae [Adverse Drug Reaction], prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], vincristine/ae [Adverse Drug Reaction], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], overall survival, cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], lenalidomide/dt [Drug Therapy], advanced cancer/di [Diagnosis], age, asymptomatic disease/di [Diagnosis], Australia, cancer combination chemotherapy, cancer diagnosis, cancer immunotherapy, cancer recurrence, cancer staging, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35707Test
Internal Medicine Journal
LibKey Link

مصطلحات الفهرس: cyclophosphamide, follicular lymphoma/dt [Drug Therapy], fludarabine, Fc receptor/ec [Endogenous Compound], cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine, acute lymphoblastic leukemia/dt [Drug Therapy], amino acid sequence, ANCA associated vasculitis/dt [Drug Therapy], antigen binding, antineoplastic activity, B cell lymphoma/dt [Drug Therapy], Burkitt lymphoma/dt [Drug Therapy], cancer immunization, cell killing, chronic lymphatic leukemia/dt [Drug Therapy], clinical trial (topic), complement dependent cytotoxicity, diffuse large B cell lymphoma/dt [Drug Therapy], down regulation, drug mechanism, drug receptor binding, event free survival, hematologic malignancy/dt [Drug Therapy], human, humoral immune deficiency/dt [Drug Therapy], idiopathic thrombocytopenic purpura/dt [Drug Therapy], immune response, immunomodulation, immunosuppressive treatment, lack of drug effect, leukemia/si [Side Effect], lymphocytic lymphoma/dt [Drug Therapy], lymphoproliferative disease/dt [Drug Therapy], marginal zone lymphoma/dt [Drug Therapy], molecularly targeted therapy, overall survival, partial drug response, pharmacokinetic parameters, progression free survival, protein degradation, protein expression, randomized controlled trial (topic), methotrexate, obinutuzumab/dt [Drug Therapy], ocrelizumab, ofatumumab/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/dt [Drug Therapy], tumor antigen/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], veltuzumab, CD20 antibody, B lymphocyte receptor/ec [Endogenous Compound], systemic lupus erythematosus/dt [Drug Therapy], smoldering multiple myeloma/dt [Drug Therapy], rheumatoid arthritis/dt [Drug Therapy], review, recombinant DNA technology, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36922Test
Human Vaccines and Immunotherapeutics
Click here for full text options
LibKey Link

مصطلحات الفهرس: prednisolone/cb [Drug Combination], adult, aged, article, bone marrow biopsy, cancer combination chemotherapy, cancer immunotherapy, cancer mortality, cancer radiotherapy, cancer recurrence, cancer staging, cohort analysis, comparative effectiveness, controlled study, distant metastasis/co [Complication], female, follicular lymphoma/dt [Drug Therapy], follicular lymphoma/rt [Radiotherapy], follow up, human, human tissue, lymph node metastasis/co [Complication], maintenance therapy, major clinical study, male, monotherapy, multimodality cancer therapy, overall survival, positron emission tomography-computed tomography, priority journal, progression free survival, radiation dose, retrospective study, survival rate, survival time, systemic therapy, treatment failure, treatment outcome, watchful waiting, bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], hemoglobin/ec [Endogenous Compound], prednisolone/dt [Drug Therapy], rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], rituximab/tm [Unexpected Outcome of Drug Treatment], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35979Test
LibKey Link

مصطلحات الفهرس: practice guideline, priority journal, thrombocytopenia/pc [Prevention], thrombocytopenia/si [Side Effect], time to treatment, tumor lysis syndrome/pc [Prevention], tumor lysis syndrome/si [Side Effect], obinutuzumab/ae [Adverse Drug Reaction], obinutuzumab/dt [Drug Therapy], infusion related reaction/si [Side Effect], article, Australia, bleeding/pc [Prevention], bleeding/si [Side Effect], cancer chemotherapy, cancer growth, cancer recurrence, drug use, follicular lymphoma/dt [Drug Therapy], human, incidence, infection/pc [Prevention], infection/si [Side Effect], infusion related reaction/pc [Prevention], maintenance therapy, medical decision making, minimal residual disease, neutropenia/si [Side Effect], positron emission tomography, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35583Test
Asia-Pacific Journal of Clinical Oncology
LibKey Link

مصطلحات الفهرس: cyclophosphamide, follicular lymphoma/dt [Drug Therapy], fludarabine, Fc receptor/ec [Endogenous Compound], cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine, acute lymphoblastic leukemia/dt [Drug Therapy], amino acid sequence, ANCA associated vasculitis/dt [Drug Therapy], antigen binding, antineoplastic activity, B cell lymphoma/dt [Drug Therapy], Burkitt lymphoma/dt [Drug Therapy], cancer immunization, cell killing, chronic lymphatic leukemia/dt [Drug Therapy], clinical trial (topic), complement dependent cytotoxicity, diffuse large B cell lymphoma/dt [Drug Therapy], down regulation, drug mechanism, drug receptor binding, event free survival, hematologic malignancy/dt [Drug Therapy], human, humoral immune deficiency/dt [Drug Therapy], idiopathic thrombocytopenic purpura/dt [Drug Therapy], immune response, immunomodulation, immunosuppressive treatment, lack of drug effect, leukemia/si [Side Effect], lymphocytic lymphoma/dt [Drug Therapy], lymphoproliferative disease/dt [Drug Therapy], marginal zone lymphoma/dt [Drug Therapy], molecularly targeted therapy, overall survival, partial drug response, pharmacokinetic parameters, progression free survival, protein degradation, protein expression, randomized controlled trial (topic), methotrexate, obinutuzumab/dt [Drug Therapy], ocrelizumab, ofatumumab/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/dt [Drug Therapy], tumor antigen/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], veltuzumab, CD20 antibody, B lymphocyte receptor/ec [Endogenous Compound], systemic lupus erythematosus/dt [Drug Therapy], smoldering multiple myeloma/dt [Drug Therapy], rheumatoid arthritis/dt [Drug Therapy], review, recombinant DNA technology, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36922Test
Human Vaccines and Immunotherapeutics
LibKey Link

مصطلحات الفهرس: infection/si [Side Effect], infusion related reaction/si [Side Effect], intention to treat analysis, major clinical study, male, multiple cycle treatment, myelodysplastic syndrome/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], non melanoma skin cancer/si [Side Effect], primary health care, priority journal, progression free survival, cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/ct [Clinical Trial], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], obinutuzumab/ae [Adverse Drug Reaction], obinutuzumab/ct [Clinical Trial], obinutuzumab/dt [Drug Therapy], obinutuzumab/iv [Intravenous Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/dt [Drug Therapy], vincristine/ae [Adverse Drug Reaction], vincristine/ct [Clinical Trial], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], randomized controlled trial, second cancer/si [Side Effect], thrombocytopenia/si [Side Effect], treatment outcome, treatment response, tumor lysis syndrome/si [Side Effect], very elderly, bendamustine/ae [Adverse Drug Reaction], bendamustine/ct [Clinical Trial], bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], adult, aged, article, bleeding disorder/si [Side Effect], cancer grading, cancer growth, cancer immunotherapy, cancer recurrence, cardiovascular disease/si [Side Effect], controlled study, digestive system perforation/si [Side Effect], female, follicular lymphoma/dt [Drug Therapy], hematologic malignancy/si [Side Effect], human, induction chemotherapy, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38731Test
New England Journal of Medicine
Click here for full text options
LibKey Link

مصطلحات الفهرس: infection/si [Side Effect], infusion related reaction/si [Side Effect], intention to treat analysis, major clinical study, male, multiple cycle treatment, myelodysplastic syndrome/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], non melanoma skin cancer/si [Side Effect], primary health care, priority journal, progression free survival, cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/ct [Clinical Trial], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], obinutuzumab/ae [Adverse Drug Reaction], obinutuzumab/ct [Clinical Trial], obinutuzumab/dt [Drug Therapy], obinutuzumab/iv [Intravenous Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/dt [Drug Therapy], vincristine/ae [Adverse Drug Reaction], vincristine/ct [Clinical Trial], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], randomized controlled trial, second cancer/si [Side Effect], thrombocytopenia/si [Side Effect], treatment outcome, treatment response, tumor lysis syndrome/si [Side Effect], very elderly, bendamustine/ae [Adverse Drug Reaction], bendamustine/ct [Clinical Trial], bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], adult, aged, article, bleeding disorder/si [Side Effect], cancer grading, cancer growth, cancer immunotherapy, cancer recurrence, cardiovascular disease/si [Side Effect], controlled study, digestive system perforation/si [Side Effect], female, follicular lymphoma/dt [Drug Therapy], hematologic malignancy/si [Side Effect], human, induction chemotherapy, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38731Test
New England Journal of Medicine
Click here for full text options
LibKey Link